Year: 2020

MONTREAL, Nov. 10, 2020 (GLOBE NEWSWIRE) — Goodfood Market Corp. (“Goodfood” or “the Company”) (TSX:FOOD), a leading online grocery Company in Canada, will release its financial results for the fourth quarter and year end of Fiscal 2020 on Wednesday, November 11, 2020, before markets open. Jonathan Ferrari, CEO, Neil Cuggy, President and COO, and Philippe Adam, CFO, will hold a conference call to review the results at 8:00 a.m. (ET) on the same day.Details of the Conference Call:When: November 11, 2020 at 8:00 a.m. ETDial in number: 877-223-4471 or 647-788-4922Conference call replay available until November 18, 2020:1-800-585-8367 or 416-621-4642To access the webcast and view the slide presentation, click on this link:https://www.makegoodfood.ca/en/investisseurs/evenementsThe conference ID is 4589249About GoodfoodGoodfood (TSX:FOOD)...

MONTRÉAL, 10 nov. 2020 (GLOBE NEWSWIRE) — Marché Goodfood Corp. (« Goodfood » ou la « Société ») (TSX : FOOD), un chef de file canadien de l’épicerie en ligne, publiera ses résultats financiers pour le quatrième trimestre ainsi que pour l’exercice financier 2020 le mercredi 11 novembre 2020, avant l’ouverture des marchés financiers. Jonathan Ferrari, chef de la direction, Neil Cuggy, président et chef des opérations, et Philippe Adam, chef de la direction financière, tiendront une conférence téléphonique à 8H00 (HE) le jour même pour présenter les résultats de la Société.Renseignements sur la conférence téléphonique :Quand : Le 11 novembre 2020 à 8H00 (HE)Numéro à composer : 877-223-4471 ou 647-788-4922Enregistrement de la conférence disponible jusqu’au 18 novembre 2020 :1-800-585-8367 ou 416-621-4642Pour écouter la conférence et...

Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility, tolerability and high T-cell persistence.Clinical courses observed in patients indicate COL6A3 exon 6 as a potentially valuable tumor target for continued evaluation.The data support further exploration of a multi-target ACT approach using potent T cell receptors (TCRs)            Tuebingen, Germany and Houston, Texas, November 10, 2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today that the Company will present Phase I results from their ACTolog® program IMA101 at the 35th Annual SITC Meeting, held virtually from November 9-14, 2020. ACTolog® is a pilot study for a personalized...

Immatics konnte die Durchführbarkeit und Verträglichkeit seiner adoptiven Zelltherapie (ACT) IMA101 zeigen, welche körpereigene T-Zellen gegen mehrere definierte pHLA Zielstrukturen gleichzeitig einsetzt – ein sogenannter Multi-Target-Ansatz. Die Behandlung führte zu einer hohen Konzentration tumorspezifischer T-Zellen im Blut.Die klinischen Verläufe der Patienten deuten auf COL6A3 Exon 6 als vielversprechende Tumorzielstruktur für eine weitere Evaluierung hin.Die Daten befürworten außerdem die weitere Untersuchung eines Multi-Target ACT-Ansatzes mit potenteren T-Zell-Rezeptoren (TCRs).      Tübingen, Deutschland und Houston, Texas, 10. November, 2020 – Immatics N.V. (NASDAQ: IMTX, „Immatics”), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-Zell-basierten Immuntherapien für die Behandlung von Krebs fokussiert,...

– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 –– Phase 1/2 clinical trials for FTD-GRN and Krabbe expected to initiate in 1H21 –– Completion of dedicated manufacturing suite achieved to ensure control of supply of company’s lead products through early commercialization – – Management to host conference call today at 8:30 a.m. ET –

RAMSEY, N.J. and BOCA RATON, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on Tuesday, November 17, 2020, at 7:55 a.m. ET.A webcast of the event will be available on the Company’s website at https://ir.admabiologics.com/events-webcasts and will be archived for 90 days following the event.About ADMA Biologics, Inc. (ADMA)ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics...

CONVERSE, Tx., Nov. 10, 2020 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) expands its presence in the San Antonio market with a new community in Converse, Texas, Hightop Ridge. This new community, located northeast of downtown San Antonio, offers stunning, upgraded homes starting in the $240s.Hightop Ridge showcases a variety of one- and two-story homes with three to five bedrooms ranging in size from 1,414 square feet to just over 2,500 square feet. Every new construction home at Hightop Ridge is outfitted with LGI Homes’ CompleteHome Plus™ package showcasing designer-selected features and modern finishes. Interior upgrades found exclusively in these homes include sprawling granite countertops, a full suite of stainless steel Whirlpool® appliances, oversized wood cabinetry with crown molding, luxury vinyl-plank flooring and...

Charlotte, N.C., Nov. 10, 2020 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that senior management will attend the Craig-Hallum Alpha Select Conference on November 17, 2020.Meetings will take place virtually on November 17, 2020 given the ongoing call for social distancing due to the Covid-19 pandemic. Investors that would like to schedule a meeting with Akoustis management should contact their Craig-Hallum representative or Akoustis’ investor relations at ir@akoustis.com.Akoustis’ high frequency, high performance XBAW process and filters are experiencing growing interest as the Company has entered production in multiple markets...

DENVER, Nov. 10, 2020 (GLOBE NEWSWIRE) — Centennial Resource Development, Inc. (“Centennial” or the “Company”) (NASDAQ: CDEV) today announced that Sean R. Smith, Chief Executive Officer, is scheduled to present at the Bank of America Securities Global Energy Conference to be held virtually on Thursday, November 12, 2020 at 12:00 p.m. Eastern. The live webcast will be available on Centennial’s website at www.cdevinc.com under the Investor Relations tab.About Centennial Resource Development, Inc.Centennial Resource Development, Inc. is an independent oil and natural gas company focused on the development of unconventional oil and associated liquids-rich natural gas reserves in the Permian Basin. The Company’s assets and operations, which are held and conducted through Centennial Resource Production, LLC, are concentrated in the Delaware...

Company intends to shorten fully-enrolled Phase 3 dermatomyositis trial to 28 weeks from 52 weeks following recent developments in competitive landscape; data now expected as early as the second quarter of 2021Expected cash runway extended into second quarter of 2022 as a result of Company restructuring, with potential to extend cash runway even further due to shortening Phase 3 dermatomyositis trialCompany will also focus on progressing pipeline compounds toward clinical testingReported topline data from RESOLVE-1 Phase 3 study of lenabasum in systemic sclerosis and data from Phase 2b study of lenabasum in cystic fibrosis; Corbus is exploring potential next steps in both indicationsCompany to host conference call and webcast today, Tuesday, November 10, 2020 at 8:30 a.m. ETNorwood, MA, Nov. 10, 2020 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals...